Our mission is to develop best in class drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs.

The Company’s lead program, solabegron, is a highly potent and selective beta-3 adrenoceptor agonist that is being developed for overactive bladder (OAB). OAB is a condition that affects the quality of life for more than 80 million people worldwide − a number that will continue to grow as the population ages.

Solabegron was discovered and first developed by GlaxoSmithKline. It was acquired by AltheRx, which merged with Velicept in 2015 to continue development of the program.  Solabegron has been tested in over 800 study subjects in a twice-a-day formulation and demonstrated efficacy in the treatment of OAB as well as IBS. A once daily formulation designed to optimize patient convenience as well as efficacy has been developed and is currently being evaluated in a phase 2b dose ranging clinical trial. A Phase 2b dose ranging study with the twice daily formulation also began enrollment in Q1 2018.

Our experienced team of pharmaceutical and biotechnology executives have a proven track record of developing, registering and commercializing new products. Velicept is a portfolio company of NeXeption.